<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28284">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01726816</url>
  </required_header>
  <id_info>
    <org_study_id>009-KOA-1201i</org_study_id>
    <nct_id>NCT01726816</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy</brief_title>
  <official_title>A Phase II, Multicenter, Randomized, Double Blind, Double-dummy, 16-week, Placebo Controlled Study to Evaluate the Efficacy and Safety of Probucol in Patients With Nephropathy Due to Type 2 Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co.,Ltd.</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is randomized, placebo-controlled, double blind, double dummy, multi-centre
      trial.

        -  Screening period (4 week)

        -  Double blind treatment period (16 weeks)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Usage: 16 week, BID, Prescribed Oral with the breakfast and dinner

        2. Dosage:Placebo group: placebo 2 tablets, 16 weeks Probucol 250mg group: probucol 125mg
           2 tablets, 16 weeks Probucol 500mg group: probucol 250 mg 2 tablets, 16 weeks
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>A/C ratio</measure>
    <time_frame>16 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in the A/C ratio from baseline to the end of treatment(16 week) [Time Frame: baseline to 16 weeks]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>16 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in the Serum creatinine from baseline to the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR</measure>
    <time_frame>16 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in the eGFR from baseline to the end of treatment(16 week)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cystatin C</measure>
    <time_frame>16 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in the cystatin C from baseline to the end of treatment(16 week)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine albumin</measure>
    <time_frame>16 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in the urine albumin from baseline to the end of treatment(16 week)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P/C ratio</measure>
    <time_frame>16 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in the P/C ratio from baseline to the end of treatment(16 week)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>16 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in the Total cholesterol from baseline to the end of treatment(16 week)</description>
  </other_outcome>
  <other_outcome>
    <measure>Triglyceride</measure>
    <time_frame>16 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in the Triglyceride from baseline to the end of treatment(16 week)</description>
  </other_outcome>
  <other_outcome>
    <measure>LDL-C</measure>
    <time_frame>16 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in the LDL-C from baseline to the end of treatment(16 week)</description>
  </other_outcome>
  <other_outcome>
    <measure>HDL-C</measure>
    <time_frame>16 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in the HDL-C from baseline to the end of treatment(16 week)</description>
  </other_outcome>
  <other_outcome>
    <measure>oxidized LDL</measure>
    <time_frame>16 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in the oxidized LDL from baseline to the end of treatment(16 week)</description>
  </other_outcome>
  <other_outcome>
    <measure>d-ROM</measure>
    <time_frame>16 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in the d-ROM from baseline to the end of treatment(16 week)</description>
  </other_outcome>
  <other_outcome>
    <measure>urinary fibronectin</measure>
    <time_frame>16 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in the urinary fibronectin from baseline to the end of treatment(16 week)</description>
  </other_outcome>
  <other_outcome>
    <measure>urinary transferrin</measure>
    <time_frame>16 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in the urinary transferrin from baseline to the end of treatment(16 week)</description>
  </other_outcome>
  <other_outcome>
    <measure>insulin</measure>
    <time_frame>16 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in the insulin from baseline to the end of treatment(16 week)</description>
  </other_outcome>
  <other_outcome>
    <measure>c-peptide</measure>
    <time_frame>16 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in the c-peptide from baseline to the end of treatment(16 week)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>Probucol 250mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probucol 250mg group: probucol 250mg 2 tablets, 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probucol 500mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probucol 500mg group: probucol 250mg 2 tablets, 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group: placebo 2 tablets, 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probucol 250mg/day</intervention_name>
    <description>Probucol 250mg + Placebo</description>
    <arm_group_label>Probucol 250mg/day</arm_group_label>
    <other_name>Probucol 250mg group: probucol 250mg 2 tablets, 16 weeks</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probucol 500mg/day</intervention_name>
    <description>Probucol 500mg + Placebo</description>
    <arm_group_label>Probucol 500mg/day</arm_group_label>
    <other_name>Probucol 500mg group: probucol 250mg 2 tablets, 16 weeks</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Probucol matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo 2 tablets, 16 weeks</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject is male or female diagnosed with type 2 diabetes mellitus and must be
             aged 20 to 75 years at the time of screening visit

          2. Urinary albumin excretion &gt; 300 mg/g Cr at screening visit

          3. Subjects administered ACEI or ARB without changing dosage prior to 3 months at the
             screening visit (if subjects administered ACEI or ARB)

          4. Subjects administered statins without changing dosage prior to 3 months at the
             screening visit(if subjects administered statins) or subjects have no plan to
             administered to statin(if subjects is not administered statin)

          5. 15 mL/min ≤ eGFR ≤ 90 mL min

          6. Subjects must be willing and able to give signed and dated written informed consent.

        Exclusion Criteria:

          1. Type 1 DM or gestational diabetes

          2. Subjects on Renal replacement therapy or Renal transplantation prior to Screening
             visit

          3. Ventricular arrhythmia (multiple and multifocal premature ventricular contractions)

          4. Cardiac damage (abnormally levels of Troponin I)

          5. Subject with medical history of cardiac syncope or primary syncope

          6. Has condition that may prolong QTc interval (for man QTc interval＞450msec, for woman
             QTc interval＞470msec) at screening

          7. Pregnant or lactating woman before randomization

          8. Inflammatory bowel disease (ulcerative colitis, Crohn's disease)

          9. Cholestasis

         10. Congestive heart failure

         11. Subjects with a myocardial infarction, Unstable angina, or cerebral infarction within
             the latest 6 months

         12. Subjects has a diagnosis of NYHA grade III-IV status

         13. AST or ALT is 3.0 times higher than the upper limit of the normal range

         14. Active hepatitis Or Liver cirrhosis

         15. Subjects with Hyperkalemia (K&gt;5.5 mEq/L)

         16. Subjects with Renal Artery stenosis

         17. Subjects with Malignancy within the 5 years at the time of screening visit(except for
             treated Basal cells carcinoma or squamous cell carcinoma)

         18. Urinary tract disease (urinary tract infection, Neurogenic bladder)

         19. Kidney disease (nephritis, chronic glomerulonephritis or polycystic kidney disease)

         20. Has an allergic history to probucol

         21. HbA1c &gt; 9%

         22. Systolic blood pressure ≥ 160 mmHg or Diastolic blood pressure ≥ 100 mmHg

         23. Subjects taken probucol within 3 months prior to Screening

         24. The subject has received an investigational product or biological agent within 3
             months prior to screening

         25. Subjects otherwise judged by the investigator or sub investigator to be inappropriate
             for inclusion in the trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MoonKyu Lee, professor</last_name>
    <role>Study Chair</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaejin Nah</last_name>
    <email>jjnah@otsuka.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mihwa Kim</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Catholic university of Korea, Bucheon St. Mary's Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>SungRae Kim, MD.PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>DaeGu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hyoung Woo LEE, MD.PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University</name>
      <address>
        <city>DaeGu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>In Kyu Lee, MD.PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>InCheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>MoonSuk Nam, MD.PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gil Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>IeByung Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonbuk national University Hospital</name>
      <address>
        <city>JeonJu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>TaeSon Park, MD.PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bong Soo Cha, MD.PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsumg Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>MoonKyu Lee, MD.PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>JiChul Bae, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>SungHwan Seo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>SeWon Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>SangMan Chin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>NaKyung Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Cheol Young Park, MD.PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sei Hyun Baek, MD.PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kangnam Sacred Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>JaeMyung Yu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eulji Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>KyungAh Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyunghee Univ Hospital at Kangdong</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yuchul Hwang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>SungNam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sung-Hee Choi, MD.PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>SeungHyun Ko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UIJEONGBU ST. MARY's HOSPITAL</name>
      <address>
        <city>Uijeongbu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>TaeSeo Son, MD.PhD</last_name>
    </contact>
    <investigator>
      <last_name>TaeSeo Son, MD.PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 17, 2013</lastchanged_date>
  <firstreceived_date>October 31, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic nephropathy</keyword>
  <keyword>Albumin creatinine ratio</keyword>
  <keyword>Probucol</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Probucol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
